University of Passo Fundo, Passo Fundo, Brazil.
J Bras Pneumol. 2013 Mar-Apr;39(2):181-9. doi: 10.1590/s1806-37132013000200009.
To evaluate the diagnostic contribution of molecular analysis of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in patients suspected of having mild or atypical cystic fibrosis (CF).
This was a cross-sectional study involving adolescents and adults aged > 14 years. Volunteers underwent clinical, laboratory, and radiological evaluation, as well as spirometry, sputum microbiology, liver ultrasound, sweat tests, and molecular analysis of the CFTR gene. We then divided the patients into three groups by the number of mutations identified (none, one, and two or more) and compared those groups in terms of their characteristics.
We evaluated 37 patients with phenotypic findings of CF, with or without sweat test confirmation. The mean age of the patients was 32.5 ± 13.6 years, and females predominated (75.7%). The molecular analysis contributed to the definitive diagnosis of CF in 3 patients (8.1%), all of whom had at least two mutations. There were 7 patients (18.9%) with only one mutation and 26 patients (70.3%) with no mutations. None of the clinical characteristics evaluated was found to be associated with the genetic diagnosis. The most common mutation was p.F508del, which was found in 5 patients. The combination of p.V232D and p.F508del was found in 2 patients. Other mutations identified were p.A559T, p.D1152H, p.T1057A, p.I148T, p.V754M, p.P1290P, p.R1066H, and p.T351S.
The molecular analysis of the CFTR gene coding region showed a limited contribution to the diagnostic investigation of patients suspected of having mild or atypical CF. In addition, there were no associations between the clinical characteristics and the genetic diagnosis.
评估囊性纤维化跨膜电导调节因子(CFTR)基因突变分析对疑似有轻度或非典型囊性纤维化(CF)的患者的诊断价值。
这是一项横断面研究,纳入了年龄>14 岁的青少年和成人志愿者。志愿者接受了临床、实验室和影像学评估,以及肺功能检查、痰微生物学检查、肝脏超声检查、汗液检查和 CFTR 基因突变分析。随后,我们根据患者基因突变数量(无、1 个或 2 个或更多个)将患者分为三组,并比较了各组患者的特征。
我们评估了 37 例具有 CF 表型表现的患者,其中有或无汗液检查结果证实。患者的平均年龄为 32.5±13.6 岁,女性居多(75.7%)。分子分析有助于明确诊断 3 例(8.1%)CF 患者,这 3 例患者均有至少 2 个基因突变。7 例(18.9%)患者只有 1 个突变,26 例(70.3%)患者无突变。我们评估的所有临床特征均与基因诊断无关。最常见的突变为 p.F508del,见于 5 例患者。p.V232D 和 p.F508del 的组合突变见于 2 例患者。其他突变包括 p.A559T、p.D1152H、p.T1057A、p.I148T、p.V754M、p.P1290P、p.R1066H 和 p.T351S。
CFTR 基因突变分析对疑似有轻度或非典型 CF 的患者的诊断调查的贡献有限。此外,临床特征与基因诊断之间无关联。